EC approves AbbVie's upadacitinib as first JAK inhibitor for atopic dermatitis
Unlike the FDA, the European Commission isn’t hesitating before handing marketing authorization to Rinvoq as the first JAK inhibitor to treat moderate and severe atopic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.